```html

Wegener's Granulomatosis (Remission)

Overview

Wegener’s granulomatosis, now more commonly called granulomatosis with polyangiitis (GPA), is a rare, autoimmune vasculitis that causes inflammation of small‑ and medium‑sized blood vessels, particularly in the upper respiratory tract, lungs, and kidneys. The disease can progress rapidly, but with modern therapy many patients achieve long‑term remission.

• Incidence: Approximately 3 cases per 100,000 adults per year in the United States.<sup>[1]</sup>
• Typical age of onset: 40–60 years, though it can occur in children and older adults.
• Gender distribution: Slight male predominance (≈55 % male).
• Geography: Occurs worldwide; no clear racial predilection.

Because GPA is an autoimmune disease, the immune system mistakenly attacks the body’s own blood vessels, leading to granuloma formation (clusters of inflammatory cells) and tissue damage. Early recognition and aggressive treatment are essential to prevent irreversible organ injury.

Symptoms

The hallmark of GPA is a triad of involvement of the upper respiratory tract, lower respiratory tract, and kidneys. However, virtually any organ system may be affected, producing a wide spectrum of clinical features.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, and purulent discharge.
• Nasopharyngeal ulceration – painful sores on the palate or nasal septum.
• Otitis media – middle‑ear inflammation causing hearing loss or ear fullness.
• Otitis externa or mastoiditis – less common but possible.

Lower Respiratory Tract

• Cough – often dry, but may become productive if pulmonary hemorrhage occurs.
• Hemoptysis – coughing up blood, a red‑flag symptom indicating alveolar capillaritis.
• Shortness of breath – due to lung infiltrates or fibrosis.
• Chest pain – pleuritic pain from inflammation of the lining of the lungs.

Kidneys

• Hematuria – blood in the urine, often microscopic at first.
• Proteinuria – protein loss in urine, a sign of glomerular injury.
• Rapidly progressive glomerulonephritis – can lead to renal failure within weeks if untreated.

Systemic and Other Organ Manifestations

• Fever, fatigue, weight loss – nonspecific but common.
• Arthralgia or arthritis – joint pain without swelling.
• Skin lesions – petechiae, purpura, or painful nodules (often on lower extremities).
• Eye involvement – scleritis, conjunctivitis, or orbital inflammation.
• Neurologic symptoms – mononeuritis multiplex (patchy nerve loss) or peripheral neuropathy.
• Gastrointestinal – abdominal pain, melena, or perforation (rare).

Causes and Risk Factors

The exact trigger for GPA remains unknown, but research points to a combination of genetic susceptibility and environmental exposure that leads to the production of anti‑neutrophil cytoplasmic antibodies (ANCA), particularly proteinase‑3 (PR3‑ANCA).

Key contributors

• ANCA antibodies – >90 % of active GPA patients have PR3‑ANCA; these antibodies activate neutrophils, causing vascular damage.
• Genetic factors – HLA‑DPB1*04 and other loci are modestly associated with increased risk.<sup>[2]</sup>
• Environmental triggers – exposure to silica dust, certain drugs (e.g., propylthiouracil, hydralazine), and infections have been implicated.

Who is at higher risk?

• Adults aged 40‑60 years.
• People with a family history of autoimmune disease.
• Occupational exposure to silica or metal dust (e.g., mining, construction).
• Individuals on long‑term use of certain medications that can induce ANCA‑associated vasculitis.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often tissue biopsy.

Laboratory tests

• ANCA testing – ELISA for PR3‑ANCA (c‑ANCA pattern) is the most specific test; a negative result does not rule out disease.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Serum creatinine & eGFR – assess kidney function.
• Urinalysis – looks for hematuria and proteinuria.
• Inflammatory markers – ESR and CRP are often elevated.

Imaging

• Chest X‑ray / CT scan – reveals nodules, cavitary lesions, or diffuse infiltrates.
• Sinus CT – evaluates chronic sinusitis, bony destruction, or mucosal thickening.

Biopsy

A tissue sample from an affected organ (e.g., nasal mucosa, lung, kidney) showing necrotizing granulomatous inflammation and small‑vessel vasculitis confirms the diagnosis. Biopsy is especially important when ANCA results are inconclusive.

Diagnostic Criteria

The 2022 ACR/EULAR classification criteria for GPA assign weighted points to clinical features, ANCA status, and histopathology. A score ≥5 yields a classification of GPA with >90 % sensitivity and specificity.<sup>[3]</sup>

Treatment Options

Therapy aims to induce remission quickly, then maintain it with lower‑intensity medication to limit side effects.

Induction therapy (remission‑inducing)

• Glucocorticoids – high‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone pulses (500‑1000 mg daily for 3 days) until disease control.
• Rituximab – anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or 1 g on days 1 and 15. Shown non‑inferior to cyclophosphamide in the RAVE trial.<sup>[4]</sup>
• Cyclophosphamide – IV pulses (15 mg/kg every 2‑3 weeks) or oral (2 mg/kg/day) for 3–6 months; used when rituximab contraindicated.
• Plasma exchange (PLEX) – considered for severe pulmonary‑renal syndrome or rapidly progressive glomerulonephritis (based on the PEXIVAS trial).

Maintenance therapy (to keep remission)

• Rituximab – 500 mg every 6 months for 2‑4 years is common.
• Azathioprine – 2 mg/kg/day.
• Mycophenolate mofetil – 1–1.5 g twice daily (alternative for those intolerant to azathioprine).
• Low‑dose glucocorticoids – taper to ≤5 mg/day of prednisone after remission.

Adjunctive measures

• Prophylaxis for opportunistic infections – trimethoprim‑sulfamethoxazole (TMP‑SMX) 1 tablet daily reduces Pneumocystis jirovecii pneumonia risk.
• Bone health – calcium, vitamin D, and bisphosphonates when long‑term steroids are used.
• Vaccinations – pneumococcal, influenza, and COVID‑19 vaccines (non‑live) before immunosuppression.

Living with Wegener's Granulomatosis (Remission)

Even when disease activity is low, ongoing self‑care and monitoring are crucial.

Medication adherence

• Take immunosuppressants exactly as prescribed – missed doses can trigger relapse.
• Keep a medication diary or use reminder apps.

Regular monitoring

• Lab work (CBC, renal function, ANCA titer) every 1–3 months for the first year, then every 3–6 months.
• Urine analysis at each visit to detect early kidney involvement.
• Annual chest imaging if prior lung disease was present.

Lifestyle recommendations

• Stop smoking – smoking worsens lung disease and interferes with medication efficacy.
• Balanced diet – adequate protein, low sodium (to protect kidneys), and plenty of fruits/vegetables.
• Physical activity – moderate aerobic exercise 150 min/week improves stamina and bone health.
• Stress management – mindfulness, yoga, or counseling can help with medication side‑effects and anxiety.
• Sun protection – some drugs increase photosensitivity.

Support resources

• Vasculitis Foundation (www.vasculitisfoundation.org) – patient education and support groups.
• National Organization for Rare Disorders (NORD) – rare‑disease resources.
• Local rheumatology or nephrology clinics – many offer multidisciplinary care teams.

Prevention

Because GPA is autoimmune, true primary prevention is not possible. However, risk reduction strategies include:

• Avoiding occupational exposure to silica dust or heavy metals (use protective equipment).
• Promptly treating chronic sinus infections to reduce inflammatory burden.
• Using medications known to trigger ANCA vasculitis only when clearly indicated and under close monitoring.
• Maintaining up‑to‑date vaccinations to lower infection‑related immune activation.

Complications

If disease activity persists or relapses, organ damage may become irreversible.

• Renal failure – up to 30 % of untreated patients progress to end‑stage renal disease requiring dialysis.
• Permanent lung fibrosis – can cause chronic respiratory insufficiency.
• Hearing loss – from chronic otitis media or eustachian tube dysfunction.
• Vision loss – scleritis or orbital granulomas may threaten eyesight.
• Peripheral neuropathy – can be disabling if not addressed early.
• Medication‑related toxicities – cyclophosphamide can cause hemorrhagic cystitis, infertility, and malignancy; long‑term steroids cause osteoporosis, diabetes, and hypertension.

When to Seek Emergency Care

References

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org (accessed June 2026).
2. Yates M, et al. Genetic susceptibility to ANCA‑associated vasculitis. Nat Rev Rheumatol. 2021;17:363‑376.
3. American College of Rheumatology/European League Against Rheumatism. 2022 classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74:227‑240.
4. Stone JH, et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. N Engl J Med. 2010;363:221–232.
5. WAARK­–PLEXIVAS Investigators. Plasma exchange for severe ANCA‑associated vasculitis. NEJM. 2020;382:1428‑1437.

```